Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Sufentanil

• Status: Not yet recruiting
• Trial end date: 2023-03-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will examine how sufentanil (a commonly used pain medication) will alter responses to simulated blood loss in humans. To simulate blood loss in the research laboratory, participants will complete a test with their lower body in a custom-designed vacuum chamber for a brief period of time.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Treatments: Sufentanil

Criteria

Inclusion Criteria:

• 18-45 years of age

• Healthy

• Non-obese (body mass index less than 30 kg/m2)

• Body mass greater than or equal to 65 kg

• Speak English

Exclusion Criteria:

• Subjects not in the defined age range

• Subjects who have cardiac, respiratory, neurological and/or metabolic illnesses

• Any known history of renal or hepatic insufficiency/disease

• Pregnancy or breast feeding

• Body mass less than 65 kg

• Current smokers, as well as individuals who regularly smoked within the past 3 years

• Subjects who cannot speak or read English

• Positive urine drug screen

• Currently taking pain modifying medication(s)